<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877474</url>
  </required_header>
  <id_info>
    <org_study_id>PM1183-A-001-08</org_study_id>
    <nct_id>NCT00877474</nct_id>
  </id_info>
  <brief_title>Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic&#xD;
      study of PM01183 for patients with advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic&#xD;
      study of PM01183 for patients with advanced solid tumors to identify the dose limiting&#xD;
      toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD)&#xD;
      of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients with&#xD;
      advanced solid tumors and to preliminarily determine the pharmacokinetics of PM01183, to&#xD;
      evaluate the antitumor activity of PM01183 and the safety and tolerability of PM01183.&#xD;
      Besides this study will evaluate the pharmacogenomics in tumor samples and peripheral white&#xD;
      blood cells (PWBCs) of patients exposed to PM01183 at the RD in order to assess potential&#xD;
      markers of response and/or resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the dose limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients with advanced solid tumors.</measure>
    <time_frame>Along the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To preliminarily determine: pharmacokinetics, antitumor activity and safety of PM01183 and to determine pharmacogenomics in tumor samples and peripheral white blood cells (PWBCs) at the RD</measure>
    <time_frame>Along the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>ADVANCED SOLID TUMORS</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PM01183</intervention_name>
    <description>Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written informed consent of the patient obtained before any study-specific&#xD;
             procedure.&#xD;
&#xD;
          2. Patients with histologically/cytologically confirmed diagnosis of advanced solid&#xD;
             tumors refractory to standard therapy or for whom no standard therapy exist (excluding&#xD;
             primary central nervous system tumors).&#xD;
&#xD;
          3. Age ≥ 18 years.&#xD;
&#xD;
          4. Patients with measurable or non-measurable disease according to RECIST.&#xD;
&#xD;
          5. Patients entered at the expansion cohort of the RD must have:&#xD;
&#xD;
               -  Measurable disease according to RECIST and/or, evaluable disease by serum markers&#xD;
                  in the case of prostate and ovarian cancer [according to the Prostate-Specific&#xD;
                  Antigen Working Group Recommendations (PSAWGR) and the Gynecologic Cancer&#xD;
                  Intergroup (GCIG) specific criteria, respectively].&#xD;
&#xD;
               -  Confirmed progressive disease after last therapy, before study initiation.&#xD;
&#xD;
               -  Available tumor samples (if pharmacogenomic study consented).&#xD;
&#xD;
          6. Recovery from any drug-related adverse event derived from any previous treatment,&#xD;
             excluding alopecia and grade ≤ 1 asymptomatic peripheral neuropathy according to the&#xD;
             National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)&#xD;
             v.3.0.&#xD;
&#xD;
          7. Laboratory values within seven days prior to first infusion:&#xD;
&#xD;
               -  Platelet count ≥ 100 x109/l, hemoglobin &gt; 9 g/dl (patients can be transfused as&#xD;
                  clinically indicated prior to study entry) and absolute neutrophils count (ANC) ≥&#xD;
                  1.5 x109/l.&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x the upper limit of normality (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 2.5 x ULN.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤ 2.5 x ULN.&#xD;
&#xD;
               -  Total bilirubin ≤ ULN. f) Calculated creatinine clearance: ≥ 40 ml/min&#xD;
                  (calculated using the Cockcroft and Gault formula).&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dl.&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          8. Women of childbearing potential must have a negative serum pregnancy test before study&#xD;
             entry. Both men and women must agree to use a medically acceptable method of&#xD;
             contraception throughout the treatment period and for 6 months after discontinuation&#xD;
             of treatment. Acceptable methods of contraception include: intrauterine conceptive&#xD;
             device (IUD), oral contraceptives, subdermal implant and double barrier (condom with a&#xD;
             contraceptive sponge or contraceptive suppository).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Less than three weeks from radiation therapy (six weeks in case of extensive prior&#xD;
             radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy&#xD;
             (six weeks in case of nitrosoureas, mitomycin C, trastuzumab, bicalutamide or&#xD;
             high-dose chemotherapy).&#xD;
&#xD;
          3. Evidence of progressive Central Nervous System (CNS) metastases or any symptomatic&#xD;
             brain or leptomeningeal metastases.&#xD;
&#xD;
          4. Patients for whom non-standard surgery approach may result in tumor free survival or&#xD;
             significant palliation.&#xD;
&#xD;
          5. Other relevant diseases or adverse clinical conditions:&#xD;
&#xD;
               -  Increased cardiac risk: symptomatic and/or medication requiring congestive heart&#xD;
                  failure or clinically relevant valvular heart disease or unstable angor pectoris&#xD;
                  or myocardial infarction within 12 months before inclusion in the study, or ≥&#xD;
                  grade 1 arrhythmia or any grade requiring treatment, or uncontrolled arterial&#xD;
                  hypertension (≥ 160/100 mmHg) despite optimal medical therapy.&#xD;
&#xD;
               -  History of significant neurological or psychiatric disorders.&#xD;
&#xD;
               -  Active infection.&#xD;
&#xD;
               -  Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic&#xD;
                  hepatitis).&#xD;
&#xD;
               -  Immunocompromised patients, including those known to be infected by human&#xD;
                  immunodeficiency virus (HIV).&#xD;
&#xD;
               -  Any other major illness that, in the investigator's judgment, will substantially&#xD;
                  increase the risk associated with the patient's participation in this study.&#xD;
&#xD;
          6. Limitation of the patient's ability to comply with the treatment or to follow-up at a&#xD;
             participating protocol. Patients registered on this trial must be treated and followed&#xD;
             at a participating center.&#xD;
&#xD;
          7. Prior treatment with any investigational product in the period ≥ 5 half-lives of the&#xD;
             investigational compound prior to the first infusion.&#xD;
&#xD;
          8. Known hypersensitivity to any of the components of the drug product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ratain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Research Center. University of Chicago Hospitals.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Tabernero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron University Hospital. Barcelona (Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Center. University of Chicago Hospitals.</name>
      <address>
        <city>Chicago,</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PM01183</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>PharmaMar USA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

